Sponsored By:

A Big Trade on Big Pharma

Don't worry about Bristol-Myers' expected earnings slide

   

Bristol-Myers Squibb (NYSE:BMY) – This leading drugmaker with a strong global emphasis in cardiovascular, anti-infective and anti-cancer therapeutics raised its dividend late last year to $1.36. The company has a long history of regular increases, and the latest brings its dividend yield to 4.11%. Although earnings are expected to decline to $1.95 this year vs. $2.16 in 2011 because of the expiration of patents, the company plans to expand its portfolio of drugs, and cost restructuring should help the bottom line.

The consensus price objective for 2012 is $38, which from the view of technical analysis appears achievable.

BMY A Big Trade on Big Pharma

chart key A Big Trade on Big Pharma


Article printed from InvestorPlace Media, http://investorplace.com/2012/05/a-big-trade-on-big-pharma-bmy/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.